Personalized Neoantigen Peptide Vaccine Helps Patient With Advanced Bile Duct Cancer
A patient with advanced intrahepatic cholangiocarcinoma benefited from personalized neoantigen peptide immunotherapy, demonstrating the potential of tumor-specific peptide vaccines for rare cancers.
Quick Facts
What This Study Found
Personalized neoantigen peptide immunotherapy induced tumor-specific immune responses and clinical benefit in a patient with advanced intrahepatic cholangiocarcinoma.
Key Numbers
Overall survival for advanced ICC is less than 1 year with standard treatments; this patient showed benefit from personalized immunotherapy.
How They Did This
Case report: whole exome sequencing to identify tumor neoantigens, peptide vaccine design, immunotherapy administration, and assessment of immune responses and clinical outcomes.
Why This Research Matters
Rare cancers like cholangiocarcinoma are often excluded from clinical trials. Personalized neoantigen vaccines offer a treatment approach that works for any cancer type, potentially transforming care for rare cancer patients.
The Bigger Picture
Personalized cancer vaccines are moving from laboratory concept to clinical reality. This case demonstrates their applicability to rare cancers that are underserved by standard treatment, suggesting that tumor-specific peptide vaccines could eventually be available for any patient regardless of cancer type.
What This Study Doesn't Tell Us
Single case report — the weakest form of evidence. Response may not be generalizable. Manufacturing individual neoantigen vaccines is time-consuming and expensive.
Questions This Raises
- ?Would neoantigen vaccination benefit other cholangiocarcinoma patients in a clinical trial?
- ?Can the manufacturing timeline be shortened to treat patients with rapidly progressing disease?
- ?How does personalized neoantigen therapy compare to standard chemotherapy for cholangiocarcinoma?
Trust & Context
- Key Stat:
- Personalized for rare cancer Neoantigen peptide vaccine designed from individual tumor mutations showed clinical benefit in a cancer type with few treatment options
- Evidence Grade:
- Preliminary evidence: single case report demonstrating feasibility and clinical benefit. Larger trials needed.
- Study Age:
- Published in 2024. Among the first applications of neoantigen immunotherapy to cholangiocarcinoma.
- Original Title:
- An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.
- Published In:
- Inflammation, 47(5), 1699-1705 (2024)
- Authors:
- Zhu, Sihui, Liu, Chenxi, Jin, Yunchen, Zhang, Hailong, Zhou, Mingzhen, Xu, Chen, Shao, Jie, Liu, Qin, Wei, Jia, Shen, Jie, Liu, Baorui
- Database ID:
- RPEP-09691
Evidence Hierarchy
Frequently Asked Questions
Can a vaccine be made specifically for my cancer?
Yes — personalized neoantigen vaccines use genetic sequencing to identify mutations unique to your tumor, then create peptides that train your immune system to attack those specific cancer cells. This approach works in principle for any cancer type.
Is this available as a treatment now?
Personalized neoantigen vaccines are available through some clinical trials and specialized cancer centers. They are not yet standard treatment due to manufacturing complexity and cost, but the field is advancing rapidly.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09691APA
Zhu, Sihui; Liu, Chenxi; Jin, Yunchen; Zhang, Hailong; Zhou, Mingzhen; Xu, Chen; Shao, Jie; Liu, Qin; Wei, Jia; Shen, Jie; Liu, Baorui. (2024). An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.. Inflammation, 47(5), 1699-1705. https://doi.org/10.1007/s10753-024-02003-8
MLA
Zhu, Sihui, et al. "An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.." Inflammation, 2024. https://doi.org/10.1007/s10753-024-02003-8
RethinkPeptides
RethinkPeptides Research Database. "An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits..." RPEP-09691. Retrieved from https://rethinkpeptides.com/research/zhu-2024-an-advanced-intrahepatic-cholangiocarcinoma
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.